Phase II Study Of OSI-774 In Advanced Esophageal Cancer
I. Determine the objective response rate in patients with advanced carcinoma of the
esophagus or gastroesophageal junction treated with erlotinib (erlotinib hydrochloride).
II. Determine the overall survival of patients treated with this drug. III. Determine the
degree of dysphagia relief in patients treated with this drug.
IV. Determine the toxicity and tolerability of this drug in these patients. V. Correlate
epidermal growth factor receptor (EGFR) expression with response to treatment in these
Patients receive erlotinib hydrochloride orally (PO) once daily (QD). Courses repeat every 4
weeks in the absence of disease progression or unacceptable toxicity.
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Major response rate (complete and partial response)
Up to 5 years
Memorial Sloan-Kettering Cancer Center
United States: Food and Drug Administration
|Memorial Sloan-Kettering Cancer Center||New York, New York 10021|